Multifactorial Aspects of Adiponectin in Non- Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a significant worldwide health issue strongly associated with obesity and metabolic syndrome. It underscores the critical role of adiponectin, a significant adipokine, in the disease's intricate progression. NAFLD's complexity stems from its interplay with factors like obesity, diabetes, and metabolic syndrome, with reduced adiponectin levels commonly observed in NAFLD patients, influenced by age, gender, lipid profiles, and insulin resistance. Adiponectin's versatility in mitigating insulin resistance, inflammation, and liver fibrosis makes it a focal point in NAFLD research, while recent studies introduce spexin, a neuropeptide, as a potential correlate, adding to the understanding of metabolic disorders. To tailor treatment approaches, recognizing the factors affecting adiponectin levels, such as genetics, lifestyle, and comorbidities, is crucial. Lifestyle changes and specific medications offer promise in improving NAFLD outcomes by modulating adiponectin. The article underscores adiponectin's central role in the complex NAFLD landscape and the need for further research to fully grasp its mechanisms and therapeutic potential in managing this prevalent liver disease, emphasizing the importance of rebalancing adipokines and enhancing metabolic health

Multifactorial Aspects Influencing Non-Alcoholic Fatty Liver Disease (Nafld)

Nonalcoholic fatty liver disease (NAFLD) is a growing public health concern, with a prevalence of up to 25% worldwide. While once considered a benign condition, NAFLD is now recognized as a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma. The pathogenesis of NAFLD is multifactorial and involves a complex interplay between genetic, environmental, and metabolic factors. In this review, we provide an overview of the multifactorial aspects of NAFLD, including genetic predisposition, insulin resistance, dyslipidemia, gut microbiota, dietary factors, and physical inactivity. We also discuss the role of inflammation, oxidative stress, and hepatic steatosis in the progression of NAFLD to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Finally, we review the current and emerging therapies for NAFLD and NASH, including lifestyle modifications, pharmacological interventions, and surgical approaches. The multifactorial nature of NAFLD requires a comprehensive approach to diagnosis, treatment, and prevention, with a focus on addressing the underlying metabolic and environmental factors that contribute to its development and progression

Vitronectin and Fetuin-A: Newfangled Glycoproteins in Periodontits and Coronary Artery Diseases: A Narrative Review

Periodontitis, an intricate inflammatory condition impacting oral support structures, is increasingly recognized as a potential contributor to systemic ailments, notably cardiovascular diseases. Its pathophysiology involves the release of inflammatory molecules like cytokines and chemokines, exacerbating conditions like atherosclerosis. Within this complex web of inflammation, glycoproteins like vitronectin and fetuin-A have emerged as pivotal players, with vitronectin's multifunctional roles in cellular processes and fetuin-A's influence on metabolic pathways. Understanding their involvement in periodontitis and cardiovascular disorders offers promise in leveraging them as diagnostic biomarkers, potentially enhancing disease management and prevention